RecruitingNot ApplicableNCT07245784

Radicle Clarity™ RBB: A Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes

Radicle Clarity™ RBB: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes


Sponsor

Radicle Science

Enrollment

850 participants

Start Date

Dec 4, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Cognitive Function and Related Health Outcomes


Eligibility

Min Age: 21 YearsMax Age: 105 Years

Inclusion Criteria21

  • Inclusion
  • Participants must meet all the following criteria:
  • Adults, at least 21 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities
  • Assigned sex at birth will determine sex-specific recruitment and surveys (male vs female) employed, when needed
  • Resides in the United States
  • Has the opportunity for at least 30% improvement in their primary health outcome
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
  • Exclusion
  • Individuals who report any of the following during screening will be excluded from participation:
  • Report being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • Reports current enrollment in another clinical trial
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Reports a current and/or recent (up to 3 months ago) major illness and/or surgery that poses a known, significant safety risk.
  • Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and/or a significant safety risk with any of the study product ingredients.
  • NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure
  • Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.
  • Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products
  • Reports current use of the primary ingredient(s) and/or similar product(s) to the active study product(s) that may limit the effects of the study products
  • Lack of reliable daily access to the internet

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTClarity Product Placebo Control

Participants will use their Clarity Product Control as directed for a period of 12 weeks

DIETARY_SUPPLEMENTClarity Active Product 1

Participants will use their Clarity Active Product (active ingredient: Himalayan Tartary buckwheat, a high-polyphenol non-grain fruit seed) as directed for a period of 12 weeks.


Locations(1)

Radicle Science Inc.

Del Mar, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07245784


Related Trials